Related Experiment Video
Updated: Mar 5, 2026
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
Potential Antitumor Activity of SIM-89 in Non-Small Cell Lung Cancer Cells
Jun Pei1, Tianqing Chu1, Minhua Shao1
1Department of Pulmonary, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.
Purpose:
c-Met and its ligand, hepatocyte growth factor (HGF), play a critical role in oncogenesis and metastatic progression. The aim of this study was to identify inhibited enzymogram and to test the antitumor activity of SIM-89 (a c-Met receptor tyrosine kinase inhibitor) in non-small cell lung cancer.
Materials And Methods:
Z'-LYTE kinase assay was employed to screen the kinase enzymogram, and mechanism of action (MOA) analysis was used to identify the inhibited kinases. Cell proliferation was then analyzed by CCK8 assay, and cell migration was determined by transwell assay. The gene expression and the phosphorylation of c-Met were examined by realtime-PCR and western blotting, respectively. Finally, the secretion of HGF was detected by ELISA assay.
Results:
c-Met, activated protein kinase (AMPK), and tyrosine kinase A (TRKA) were inhibited by SIM-89 with the IC₅₀ values of 297 nmol/L, 1.31 μmol/L, and 150.2 nmol/L, respectively. SIM-89 exerted adenosine triphosphate (ATP) competitive inhibition on c-Met. Moreover, the expressions of STAT1, JAK1, and c-Met in H460 cells were decreased by SIM-89 treatment, and c-Met phosphorylation was suppressed in A549, H441, H1299, and B16F10 cells by the treatment. In addition, SIM-89 treatment significantly decreased the level of HGF, which accounted for the activation of c-Met receptor tyrosine kinase. Finally, we showed cell proliferation inhibition and cell migration suppression in H460 and H1299 cells after SIM-89 treatment.
Conclusion:
In conclusion, SIM-89 inhibits tumor cell proliferation, migration and HGF autocrine, suggesting it's potential antitumor activity.
Insights
SIM-89, a c-Met receptor tyrosine kinase inhibitor, effectively reduced non-small cell lung cancer cell proliferation and migration. This compound also inhibited hepatocyte growth factor (HGF) secretion, indicating potential antitumor activity.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- The c-Met receptor tyrosine kinase and its ligand, hepatocyte growth factor (HGF), are crucial in cancer development and metastasis.
- Targeting c-Met is a promising strategy for non-small cell lung cancer (NSCLC) therapy.
Purpose of the Study:
- To identify the kinase inhibition profile of SIM-89.
- To evaluate the antitumor effects of SIM-89, a c-Met inhibitor, on non-small cell lung cancer cells.
Main Methods:
- Kinase inhibition screening using Z'-LYTE assay.
- Mechanism of action analysis, cell proliferation (CCK8), and migration (Transwell) assays.
- Gene expression (real-time PCR), protein phosphorylation (Western blotting), and HGF secretion (ELISA) analysis.
Main Results:
- SIM-89 inhibited c-Met, AMPK, and TRKA kinases with specific IC50 values.
- SIM-89 demonstrated ATP-competitive inhibition of c-Met and reduced c-Met phosphorylation and HGF levels.
- SIM-89 suppressed proliferation and migration in NSCLC cell lines (H460, H1299).
Conclusions:
- SIM-89 exhibits antitumor activity by inhibiting cell proliferation and migration.
- SIM-89's mechanism involves suppressing c-Met signaling and HGF autocrine.
- SIM-89 shows potential as a therapeutic agent for non-small cell lung cancer.
